文献速递肿瘤 PET/CT骨显像与常规 SPECT

AI定量¹¹C-MET PET/CT骨髓代谢活性用于新诊断多发性骨髓瘤预后评估

AI-Quantified ¹¹C-MET PET/CT bone marrow metabolic activity for prognostic assessment in newly diagnosed multiple myeloma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-30

该前瞻性研究纳入49例新诊断多发性骨髓瘤患者,开发并验证AI方法自动量化全骨骼骨髓代谢活性,基于¹¹C-MET PET/CT计算MTV和TLMU。结果显示AI定量的¹¹C-MET MTV和TLMU与临床标志物显著相关,可独立预测PFS,且预测效能优于¹⁸F-FDG PET/CT参数。

要点

  • AI可自动分割骨骼并在¹¹C-MET PET/CT上量化全骨骼骨髓MTV和TLMU。
  • ¹¹C-MET MTV和TLMU与BMPC百分比、β₂微球蛋白、ISS/R-ISS分期显著相关。
  • ¹¹C-MET MTV和TLMU独立预测PFS,AUC分别为0.743和0.749,优于¹⁸F-FDG参数。

核心结论

  • AI定量的¹¹C-MET MTV和TLMU可作为疾病负荷的客观生物标志物,独立预测MM预后,效能优于¹⁸F-FDG参数,可能改善风险分层。

研究设计与样本

  • 前瞻性研究纳入49例新诊断MM患者(中位年龄68岁,29例男性),所有患者均接受¹¹C-MET和¹⁸F-FDG PET/CT。
  • AI算法先在CT图像上分割骨骼,再将掩膜传播至SUV PET图像,实现自动PET/CT分割和骨髓代谢 volumetic 定量评估。
  • 通过应用一系列SUV阈值,算法计算¹¹C-MET MTV和TLMU,并评估其与临床标志物及PFS的关联。

主要发现

  • AI定量的¹¹C-MET MTV和TLMU与BMPC百分比显著相关(MTV: r=0.32, p=0.02;TLMU: r=0.31, p=0.03)。
  • ¹¹C-MET MTV和TLMU与血清β₂微球蛋白显著相关(MTV: r=0.29, p=0.05;TLMU: r=0.29, p=0.05)。
  • ¹¹C-MET MTV和TLMU与ISS分期显著相关(MTV: r=0.31, p=0.03;TLMU: r=0.32, p=0.03),与R-ISS分期显著相关(MTV: r=0.40, p=0.02;TLMU: r=0.37, p=0.03)。
  • 多变量Cox分析中,¹¹C-MET MTV(HR=1.0023; 95%CI: 1.0004-1.0042; p=0.02)和TLMU(HR=1.0003; 95%CI: 1.0001-1.0005; p=0.01)独立预测PFS。
  • PFS预测中,¹¹C-MET MTV(AUC=0.743; 95%CI: 0.563-0.903; p<0.01)和TLMU(AUC=0.749; 95%CI: 0.576-0.904; p<0.01)优于¹⁸F-FDG PET/CT的TLG(AUC=0.713, p<0.01)和MTV(AUC=0.719, p<0.01)。

关键数值与推荐

  • AI算法通过CT分割骨骼并传播至PET图像,应用一系列SUV阈值计算¹¹C-MET MTV和TLMU。
  • ¹¹C-MET MTV和TLMU与BMPC百分比、β₂微球蛋白、ISS和R-ISS分期的相关系数r为0.29-0.40,p值为0.02-0.05。
  • 多变量Cox分析中¹¹C-MET MTV的HR=1.0023(95%CI: 1.0004-1.0042; p=0.02),TLMU的HR=1.0003(95%CI: 1.0001-1.0005; p=0.01)。
  • PFS预测的AUC:¹¹C-MET MTV为0.743(95%CI: 0.563-0.903; p<0.01),TLMU为0.749(95%CI: 0.576-0.904; p<0.01),¹⁸F-FDG TLG为0.713(p<0.01),¹⁸F-FDG MTV为0.719(p<0.01)。

临床怎么用

  • AI定量的¹¹C-MET MTV和TLMU可作为新诊断MM的客观疾病负荷标志物,辅助风险分层。
  • ¹¹C-MET PET/CT参数在预测PFS方面可能优于¹⁸F-FDG PET/CT参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop and validate an AI method for automated quantification of whole-skeleton bone marrow (BM) metabolic activity using Carbon 11 (11C)-methionine (MET) PET/CT and to evaluate its prognostic value compared with Fluorine 18 (18F)-fluorodeoxyglucose (FDG) PET/CT in patients with newly diagnosed MM. METHODS: This prospective study included 49 patients (median age, 68 years; 29 males) with newly diagnosed MM. All patients underwent both 11C-MET and 18F-FDG PET/CT. An AI algorithm initially segments the skeleton on CT images, then propagates the resulting mask to the standardized uptake value (SUV) PET images for automated PET/CT segmentation and quantitative volumetric assessment of BM metabolism. By applying a series of SUV thresholds, the algorithm calculates 11C-MET metabolic tumor volume (MTV) and total lesion methionine uptake (TLMU). Associations with clinical markers (bone marrow plasma cell [BMPC] percentage, serum β₂-microglobulin, International Staging System [ISS]/Revised ISS [R-ISS] stage) and progression-free survival (PFS) were assessed. RESULTS: AI-quantified 11C-MET MTV and TLMU showed significant correlations with BMPC percentage (MTV: r = 0.32, p = 0.02; TLMU: r = 0.31, p = 0.03), serum β₂-microglobulin (MTV: r = 0.29, p = 0.05; TLMU: r = 0.29, p = 0.05), ISS stage (MTV: r = 0.31, p = 0.03; TLMU: r = 0.32, p = 0.03), and R-ISS stage (MTV: r = 0.40, p = 0.02; TLMU: r = 0.37, p = 0.03). In multivariable Cox analysis, both ¹¹C-MET MTV (HR = 1.0023; [95% CI: 1.0004-1.0042]; p = 0.02) and TLMU (HR = 1.0003; [95% CI: 1.0001-1.0005]; p = 0.01) independently predicted PFS. For PFS prediction, 11C-MET MTV (Area Under the Receiver Operating Characteristic Curve [AUC] = 0.743; [95% CI: 0.563-0.903]; p < 0.01) and TLMU (AUC = 0.749; [95% CI: 0.576-0.904]; p < 0.01) outperformed ¹⁸F-FDG PET/CT total lesion glycolysis (TLG) (AUC = 0.713, p < 0.01) and MTV (AUC = 0.719, p < 0.01) using the proposed thresholds. CONCLUSION: AI-quantified 11C-MET MTV and TLMU act as objective biomarkers of disease burden, they independently predict MM prognosis more effectively than 18F-FDG parameters and may enhance risk stratification.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ye Z, Lv J, Wu X, et al. AI-Quantified ¹¹C-MET PET/CT bone marrow metabolic activity for prognostic assessment in newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2025. PMID: 41165818. doi:10.1007/s00259-025-07594-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。